Treating Cushing syndrome depends entirely on what’s causing the excess cortisol. When a pituitary tumor is the source, surgery is the first-line option with remission rates up to 95% in favorable cases. When the cause is a medication you’re taking, a carefully managed taper is the path forward. And when surgery isn’t possible or doesn’t work, several medications can bring cortisol levels back toward normal. Here’s what each treatment path looks like in practice.
Treating Medication-Induced Cushing Syndrome
The most common cause of Cushing syndrome isn’t a tumor. It’s long-term use of corticosteroid medications like prednisone, prescribed for conditions such as asthma, rheumatoid arthritis, or inflammatory bowel disease. If you and your doctor determine the underlying condition is controlled well enough to reduce or stop the corticosteroid, tapering is how you reverse the syndrome.
Tapering has to be gradual because your adrenal glands, after months or years of suppression, need time to start producing cortisol on their own again. Stopping abruptly can trigger adrenal insufficiency, a potentially dangerous drop in cortisol. The speed of the taper depends on your current dose. At high doses (above 40 mg of prednisone), reductions of 5 to 10 mg per week are typical. Between 20 and 40 mg, the step down shrinks to about 5 mg per week. Once you get below 10 mg, the process slows considerably, with decreases of just 1 mg every one to four weeks.
The final stretch, getting from around 5 mg down to zero, is the hardest. Your body may resist, producing withdrawal symptoms like fatigue, joint pain, and mood changes even though cortisol levels are technically in the normal range. If withdrawal symptoms become severe, your doctor may temporarily bump the dose back up to the last level you tolerated and then resume tapering more slowly. This entire process can take weeks to months depending on how long you were on the medication and how high the dose was.
Surgery for Pituitary-Caused Cushing Disease
About 70% of endogenous Cushing syndrome (the kind your body produces on its own) comes from a small tumor in the pituitary gland that pumps out too much of the hormone ACTH, which in turn drives the adrenal glands to overproduce cortisol. This specific form is called Cushing disease, and the standard treatment is transsphenoidal surgery, where a surgeon reaches the pituitary through the nasal passages without any external incision.
Success rates depend heavily on tumor characteristics. When the tumor hasn’t invaded surrounding structures, remission rates at three months reach about 95%. When the tumor has grown into the cavernous sinus, a web of veins near the pituitary, that rate drops to around 59%. Long-term remission follows a similar pattern: roughly 77% for noninvasive tumors and 52% for invasive ones.
Even after successful surgery, recurrence is a real possibility that requires long-term monitoring. A large international study found that 10-year recurrence rates ranged from about 15% for small, genetically favorable tumors to as high as 45% for larger ones. This means regular follow-up blood and urine tests for years after surgery, even when initial results look excellent.
What Recovery Looks Like
After successful pituitary surgery, your body doesn’t bounce back immediately. The remaining healthy pituitary tissue and your adrenal glands have been suppressed by the excess cortisol, so you’ll typically need temporary hydrocortisone replacement for months. Many patients feel worse before they feel better during this period. Symptoms like fatigue, muscle weakness, and mood changes are common as your body readjusts to normal cortisol levels. Full recovery of the body’s natural cortisol production can take six months to over a year.
Surgery for Adrenal Tumors
When the problem originates in the adrenal gland itself, such as a cortisol-producing adrenal tumor, the treatment is surgical removal of the affected gland. For a single benign adrenal tumor, removing one adrenal gland is curative in nearly 100% of cases when performed by an experienced surgeon. The remaining adrenal gland eventually takes over full cortisol production, though this can take months.
Some conditions affect both adrenal glands. In bilateral macronodular adrenal hyperplasia, where both glands are enlarged with multiple nodules, the standard approach is removing both adrenal glands laparoscopically. The same is true for primary pigmented nodular adrenal disease, a rare condition where tiny dark nodules form on both glands. Removing both glands is curative in most of these cases but means you’ll need lifelong hormone replacement for both cortisol and aldosterone, since your body can no longer make either one.
Medications That Lower Cortisol
When surgery isn’t an option, hasn’t fully worked, or needs to be delayed, several classes of medication can control excess cortisol. These drugs generally fall into two categories: those that block cortisol production in the adrenal glands and those that block cortisol’s effects at the tissue level.
Cortisol Synthesis Inhibitors
These drugs work by interfering with the enzymes in the adrenal glands that manufacture cortisol. Three are commonly used, each with a different profile.
Ketoconazole, originally developed as an antifungal, is one of the most widely used. It’s typically started at 200 to 600 mg daily, split into two or three doses, with most patients achieving cortisol normalization at 600 to 800 mg per day. Severe cases may require up to 1,200 mg. Liver function needs regular monitoring because the drug can cause liver damage.
Metyrapone works faster but needs to be taken three to four times daily due to its short duration in the body. Starting doses are usually around 1,500 mg per day, increasing every few days as needed. It can cause a buildup of cortisol precursors that sometimes triggers acne, excess hair growth, or high blood pressure in some patients.
Osilodrostat is a newer option that blocks the final step of cortisol production. It’s started at a low dose of 2 mg twice daily for typical cases and adjusted upward every two to three weeks based on lab results. For severe cases, doctors may start at 10 to 20 mg daily and increase more aggressively. All cortisol synthesis inhibitors carry the risk of dropping cortisol too low, which requires careful dose titration and sometimes the addition of a small replacement dose of hydrocortisone.
A Cortisol Blocker for Metabolic Complications
Mifepristone takes a different approach. Rather than reducing cortisol production, it blocks cortisol from binding to its receptors throughout the body. It’s specifically approved for patients whose Cushing syndrome has caused type 2 diabetes or impaired glucose tolerance. In clinical trials, 60% of patients with diabetes saw clinically meaningful improvements in blood sugar control within 24 weeks. Average HbA1c (a marker of long-term blood sugar) dropped from 7.4% to 6.3%, and fasting blood glucose fell from about 149 mg/dL to 105 mg/dL. Insulin resistance also improved significantly. Because mifepristone doesn’t lower cortisol levels (it just blocks their effect), standard cortisol blood tests can’t be used to monitor treatment, making dose adjustments more reliant on clinical signs and symptoms.
A Pituitary-Targeted Medication
Pasireotide works at the source in pituitary-driven Cushing disease, targeting receptors on the pituitary tumor to reduce ACTH secretion. About 40% of patients achieve normal cortisol levels with this drug. The major downside is its effect on blood sugar: roughly half of patients develop high blood glucose or new-onset diabetes during treatment, requiring close glucose monitoring and often diabetes medication alongside it.
Radiation Therapy
Pituitary radiation is typically reserved for cases where surgery hasn’t achieved remission or the tumor has returned. It works, but slowly. The median time to remission after radiation is about 24 months, meaning half of patients wait two years or longer before seeing cortisol levels normalize. During that waiting period, most patients need medication to control cortisol. Radiation also carries a significant long-term risk of damaging the healthy pituitary gland, leading to deficiencies in other hormones like thyroid hormone, growth hormone, or sex hormones that may require lifelong replacement.
Bilateral Adrenalectomy as a Last Resort
When the source of excess ACTH can’t be found (occult ectopic ACTH syndrome), when other treatments have failed, or when a patient is critically ill from severe cortisol excess, removing both adrenal glands provides an immediate and definitive solution. Cortisol levels drop within hours. The trade-off is permanent: you’ll depend on daily cortisol and aldosterone replacement for the rest of your life, need to carry emergency injection kits for adrenal crisis situations, and wear medical alert identification. In pituitary-driven cases, there’s also a risk that the pituitary tumor grows aggressively after both adrenal glands are removed, a condition called Nelson syndrome, which requires its own monitoring and management.
Managing the Damage Cortisol Has Already Done
Even after cortisol levels are brought under control, the metabolic consequences of Cushing syndrome don’t vanish overnight. Excess cortisol causes bone loss, weight gain concentrated in the trunk and face, muscle wasting, high blood pressure, elevated blood sugar, and thinning skin that bruises easily. Many of these problems need direct treatment alongside the cortisol-lowering strategy. Bone density scans may reveal osteoporosis requiring treatment. Blood pressure and blood sugar often need their own medications until the body recovers. Physical therapy or progressive exercise helps rebuild muscle that was broken down during the period of excess cortisol.
Recovery timelines vary. Some features like the round “moon face” and central weight gain improve over months as cortisol normalizes. Others, particularly bone density and muscle strength, can take a year or more to recover. Mood and cognitive changes, which are common during active Cushing syndrome, also tend to improve but may linger. Many patients describe the recovery period as its own challenge, separate from the disease itself.